Health & Research Goals
Semax
Semax is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4–10), with the sequen…
Primary Description
Semax is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4–10), with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Developed in Russia by the Institute of Molecular Genetics, Semax is approved in Russia for clinical use in stroke recovery, cognitive impairment, and attention disorders. It is not a direct stimulant but instead enhances the brain's endogenous neurotrophic systems — primarily through upregulation of BDNF and its receptor trkB — producing cognitive enhancement without the jitteriness or crash associated with stimulants. Semax is primarily administered intranasally to facilitate direct CNS delivery via the olfactory pathway, bypassing the blood-brain barrier. It is one of the most extensively studied nootropic peptides with over 99 academic citations, decades of clinical use in Russia, and a well-established safety profile.
Key Benefits
- Enhanced cognition
- Neuroprotection
- Reduced anxiety
Store lyophilized powder at 2–8°C, away from light and moisture. Reconstituted solution should be refrigerated and used within 30 days. Available as nasal spray drops (standard Russian formulation) or as injectable grade powder. Nasal spray stable for 14–30 days at room temperature per Russian manufacturer guidelines.
Demonstrated Effects
- Clinically approved in Russia for stroke recovery and ischemic brain injury rehabilitation
- Enhances memory consolidation, learning, attention, and mental clarity
- Upregulates BDNF supporting neuroplasticity and long-term cognitive function
- Neuroprotective against oxidative stress, excitotoxicity, and ischemic damage
- Approved for attention disorders — enhances focus without stimulant side effects
- Rapid onset of cognitive effects — typically 15–30 minutes after intranasal dosing
- No sedation, dependency, or withdrawal effects reported
- May reduce ADHD-like symptoms and improve executive function
- Anti-inflammatory effects in the CNS via cytokine modulation
- Decades of clinical use in Russia with established safety profile
Proposed Mechanisms of Action
1. BDNF/trkB System Upregulation
Semax's primary mechanism involves upregulation of brain-derived neurotrophic factor (BDNF) and its receptor trkB in the hippocampus and prefrontal cortex. BDNF promotes synaptic plasticity, neurogenesis, and neuroprotection. This is the central mechanism driving cognitive enhancement and neuroprotection.
2. Dopaminergic and Serotonergic Modulation
Semax modulates dopamine and serotonin neurotransmission, contributing to improved attention, motivation, mood, and stress resilience without direct receptor agonism or the tolerance-building properties of stimulants.
3. Melanocortin Receptor Partial Agonism
As an ACTH(4-10) analogue, Semax interacts with melanocortin receptors (MC1–5R), contributing to its nootropic effects. Unlike full ACTH, Semax lacks the adrenocortical-stimulating C-terminal portion, preventing cortisol elevation.
4. Neuroprotection via Antioxidant and Anti-inflammatory Pathways
Semax reduces oxidative stress markers and modulates pro-inflammatory cytokines in the CNS, protecting neurons from ischemic and excitotoxic damage. Relevant for stroke recovery and age-related neuroprotection.
5. NMDA Receptor Modulation
Semax has been reported to modulate NMDA receptor activity, contributing to its neuroprotective and memory-enhancing effects through glutamate receptor regulation.
Research Evidence & Clinical Data
Investigated Applications
Cognitive Enhancement and Nootropic Use
Anecdotal: HighSemax is the most commonly cited peptide nootropic in the biohacker community for focus, memory, and mental performance enhancement. Users report improved clarity, faster information processing, enhanced motivation, and sharper working memory. Effects are described as clean and functional — similar to stimulants in terms of focus but without overstimulation.
Preclinical basis: Semax increases BDNF mRNA expression by 1.4–1.6x in the hippocampus and frontal cortex. Rat studies show improved maze performance and memory retention at 50–100 mcg/kg doses.
Stroke Recovery and Neuroprotection
Anecdotal: HighSemax is approved in Russia as an adjunct therapy for ischemic stroke recovery. It accelerates neurological rehabilitation by protecting peri-infarct tissue, stimulating BDNF-driven neuroplasticity, and reducing neuroinflammation. Clinical use began in Russia in the 1990s with robust evidence for functional outcome improvement.
Preclinical basis: Multiple Russian clinical trials confirmed improved neurological deficits and functional recovery post-stroke. Animal models showed reduced infarct size and accelerated motor recovery.
Attention and Executive Function
Anecdotal: ModerateSemax is used clinically in Russia for attention disorders and has attracted interest in the biohacker community as a non-stimulant option for ADHD-like symptoms. Users report improved sustained attention, reduced distractibility, and better executive function without the cardiovascular or anxiety side effects of traditional stimulants.
Preclinical basis: Approved indication in Russia for optic nerve disorders and attention deficits. Dopaminergic and serotonergic modulation contribute to attention-enhancing effects.
Mood and Stress Resilience
Anecdotal: ModerateSome users report improved mood, reduced stress reactivity, and enhanced emotional stability with Semax. This may be mediated by serotonergic modulation and BDNF's role in mood regulation, effects that overlap with antidepressant mechanisms.
Preclinical basis: Serotonergic and dopaminergic system modulation; BDNF upregulation has established antidepressant-relevant effects in preclinical models.
Safety Profile
Common Side Effects
- Mild irritability or overstimulation at high doses
- Nasal irritation from intranasal administration
- Transient headache
- Mild insomnia if dosed late in the day
- Minimal
- Nasal irritation (rare)
Contraindications
- Hypersensitivity to any component
- Active psychosis or severe psychiatric disorders (use with caution)
- Pregnancy and breastfeeding (insufficient safety data)
- Children (insufficient safety data)
- None well-established
Legal & Regulatory Status
Approved in Russia as a prescription medication for stroke treatment, optic nerve disease, and cognitive impairment. Not FDA-approved in the United States. Available as a research compound internationally. Not scheduled as a controlled substance in most jurisdictions.
Aprobado en Rusia como medicamento de prescripción para el tratamiento del accidente cerebrovascular, enfermedad del nervio óptico y deterioro cognitivo. No aprobado por la FDA en los Estados Unidos. Disponible como compuesto de investigación internacionalmente. No clasificado como sustancia controlada en la mayoría de jurisdicciones.
Research Protocols
Dosing Protocols
Routes of Administration
intranasal
subcutaneous
Reconstitution Guide
Pharmacokinetics
| Half-Life | Very short plasma half-life (~minutes). Intranasal administration delivers peptide directly to CNS via olfactory pathway; functional CNS effects persist 4–8 hours despite rapid plasma clearance. |
Monitoring & Risk Management
Ongoing Monitoring Steps
- Monitor cognitive performance and response
- Assess for any mood changes or increased anxiety
- Evaluate nasal health if using intranasal route long-term
- Periodic 1–2 week breaks to assess need and prevent adaptation
Critical Warning Signs
- Increased anxiety, agitation, or irritability
- Significant insomnia
- Persistent headache
- Paradoxical cognitive worsening
Featured in Stacking Protocols
Community-researched combinations involving this compound